Carotenoid antioxidant supplement
Astaxanthin
Astaxanthin after one dose: 50% at ~16 h, 25% at 32 h, 12.5% at 48 h.
Drawn from the half-life in the app's model, ~16 h. The model's figures
- Compound
- Astaxanthin
- Symbol
- AST
- Family
- Supplements
- Parts
- 13
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Astaxanthin is a carotenoid of the xanthophyll group, and the main natural source used commercially is the microalga Haematococcus pluvialis.2 The app files it as a carotenoid antioxidant supplement taken by mouth, with a typical range of 4–12 mg/day. In the EU, an astaxanthin-rich oleoresin from H. pluvialis is authorised in food supplements at a maximum level of 8 mg astaxanthin per day, and the first authorisation of that level was granted in Sweden in 1995.4 The app grades the evidence as moderate. The human studies described below range from 3 participants in a pharmacokinetic study to 80 in a semen trial.3,7
How it works
Sources in this part
In the introduction to their skin trial, Ito and colleagues (FUJIFILM Corporation) write that astaxanthin "exerts a strong anti-oxidative activity by scavenging free radicals" and that its scavenging effect for singlet oxygen "is approximately 1000 times higher than that of coenzyme Q10".5 The same introduction states that astaxanthin is absorbed from the small intestine and transported "to the brain by crossing the blood-brain barrier" and to the skin.5 These are literature statements the authors cite, not outcomes measured in the trial. The meta-analysis by Zhou and colleagues describes the skin-ageing rationale as astaxanthin "mitigating skin photoaging and age-related skin diseases by its antioxidant and anti-inflammatory effects in animal studies".6
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~16 h
- Bioavailability
- 50%
- Typical dose
- 4–12 mg/day
- Route
- Oral
- Time to peak
- ~6 h
The second column holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~16 h | 15.9 ± 5.3 h after 40 mg in 32 healthy men (Odeberg and colleagues); 32.66 h (SD 6.29) for a micellar and 31.76 h (SD 16.86) for a native preparation after 8 mg in 12 healthy men (Khayyal and colleagues); 52 ± 40 h after 100 mg in 3 men (Coral-Hinostroza and colleagues); a review gives about 16 h to 30 h1,2,3,6 |
| Bioavailability | 50% | Authors of the 2024 pharmacokinetic study write that oral bioavailability "ranges around 10–50% of the given dose"; a review states that absorption "ranges from 6% to 34% after 4 h"; in the 2003 study, three lipid-based formulations gave 1.7 to 3.7 times the bioavailability of the reference formulation2,6,1 |
| Time to peak | ~6 h | Mean times of 8.5 h (native) and 3.67 h (micellar) after 8 mg in 12 men; 11.5 h after 100 mg in 3 men2,3 |
| Volume of distribution, absorption rate constant | Not listed by the app | The Khayyal and colleagues table lists Cmax, Tmax, AUC0-t, AUC0-INF, T½ and λ-z (a first-order elimination rate constant), with no volume of distribution or absorption rate constant2 |
Deeper analysis: Odeberg and colleagues, European Journal of Pharmaceutical Sciences, 2003
Mercke Odeberg and colleagues (Department of Clinical Pharmacology, Lund University Hospital, Sweden) ran an open parallel study in which healthy male volunteers received a single 40 mg dose of astaxanthin as lipid-based formulations or as a commercial food supplement, then had blood sampled.1 The elimination half-life was 15.9 ± 5.3 h in 32 participants with a monophasic curve, and the three lipid-based formulations (palm oil with polysorbate 80, glycerol mono- and dioleate with polysorbate 80, and the same with sorbitan monooleate) gave 1.7 to 3.7 times the bioavailability of the reference.1 The highest bioavailability was with formulation B, which has "a high content of the hydrophilic synthetic surfactant polysorbate 80".1 The PubMed record lists no funding statement, no author ties and no adverse-event or limitation passage, so none are reported here.
Deeper analysis: Khayyal and colleagues, European Journal of Drug Metabolism and Pharmacokinetics, 2024
Khayyal and colleagues (Faculty of Pharmacy, Cairo University) compared a micellar astaxanthin preparation with a native astaxanthin-glycerol preparation in a "comparative, crossover, single-dose, two-way, open-label study" of 12 healthy male volunteers.2 Each volunteer received a 400 mg preparation equivalent to 8 mg astaxanthin with 240 mL of water, with a 1-week washout, and blood was drawn hourly for 12 h and then at 24, 48 and 72 h.2 The micellar preparation reached a Cmax of 7.21 µg/ml after 3.67 h against 3.86 µg/ml after 8.5 h for the native preparation, and the table gives half-lives of 32.66 h and 31.76 h.2 The authors report that the AUCs "were found to be not significantly different", while the table marks the Cmax and Tmax differences between the preparations with P ≤ 0.05.2 The paper states that "no clinically significant abnormalities were observed".2 The study "was funded in part by AQUANOVA AG", two authors are employed there, and the micellar test product was supplied by AQUANOVA.2 The text read contains no passage headed as limitations; the open-label, single-dose design in 12 men is stated in the methods.2
Deeper analysis: Coral-Hinostroza and colleagues, 2004
Coral-Hinostroza and colleagues (AKVAFORSK, Institute of Aquaculture Research, Norway) studied three male volunteers aged 41 to 50 years who ate a meal containing 10 mg astaxanthin equivalents as diesters, then 100 mg equivalents after 4 weeks.3 Plasma Cmax was 0.28 ± 0.1 mg/l at 11.5 h after the 100 mg dose, the elimination half-life was 52 ± 40 h, and Cmax at the low dose was 0.08 mg/l, which the authors say "showed that, the dose response was non-linear".3 With three participants and a standard deviation of 40 h around a 52 h mean, the half-life estimate is imprecise; the PubMed record lists the paper as "Research Support, Non-U.S. Gov't" and gives no funder, author ties or limitation statement.3
Human studies
Funding differs across these studies: FUJIFILM Corporation, whose employees authored the skin trial, is named as "a sponsor and funder"; the semen trial reports a capsule donation from the manufacturer; and several authors of the eye-strain trial are employed by AstaReal companies, which are subsidiaries of Fuji, by Fuji Chemical Industries, or by a contract research organisation engaged by Fuji.5,7,8
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ito and colleagues, Nutrients 20185 | Randomised, double-blind, placebo-controlled, parallel group; primary outcome minimal erythema dose (MED); FUJIFILM-employed authors5 | 23 healthy Japanese participants enrolled (21 females, 2 males), aged 30 to 56; 22 analysed5 | 4 mg astaxanthin capsule or placebo daily, 9 weeks of supplementation5 | MED rose more from baseline with astaxanthin than with placebo, but the raw MED after supplementation did not differ (48.4 ± 8.2 against 44.0 ± 6.2 mJ/cm2, p = 0.162); no difference in transepidermal water loss; no adverse events reported5 |
| Zhou and colleagues, Nutrients 20216 | Systematic review and meta-analysis of 9 randomised trials of oral astaxanthin plus 2 open-label studies; most trials of unclear risk of bias6 | Healthy adults, mostly Japanese females, in small trials (each under 100 people; 16 to 65 participants)6 | Oral supplementation, usually at least 3 mg/day; the randomised trials lasted 4 weeks to 16 weeks6 | Moisture standardised mean difference (SMD) 0.53 (95% CI 0.05 to 1.01); elasticity SMD 0.77 (95% CI 0.19 to 1.35); wrinkle depth SMD -0.26 (95% CI -0.58 to 0.06, p = 0.11), not significant6 |
| Kumalic and colleagues, Radiology and Oncology 20207 | Randomised, double-blind, placebo-controlled; capsules donated by the manufacturer7 | 80 men with oligospermia with or without asthenozoospermia or teratozoospermia, randomised; 72 completed (37 astaxanthin, 35 placebo)7 | 16 mg astaxanthin daily or placebo, 3 months7 | No semen parameter, DNA fragmentation, mitochondrial membrane potential or FSH changed with astaxanthin; sperm number and concentration rose in the placebo group (p = 0.002 and p = 0.024); no adverse effects reported7 |
| Hecht and colleagues, Advances in Therapy 20258 | Randomised, double-blind, placebo-controlled; several authors employed by AstaReal, Fuji Chemical Industries or a contract research organisation engaged by Fuji8 | 64 children aged about 11.5 to 11.7 years on average, with 4 or more hours of daily screen time and "mild to moderate" computer vision syndrome symptoms8 | 4 mg astaxanthin soft capsule daily, 84 days8 | Questionnaire (CVS-Q) score fell 4.00 ± 4.05 units with astaxanthin against 1.72 ± 3.61 with placebo, a 20% between-group difference; no significant intergroup difference in Schirmer I test, visual acuity, near point of accommodation, immune markers or safety variables8 |
Sources in this part
Deeper analysis: Ito and colleagues, skin and ultraviolet light, Nutrients 2018
Ito, Seki and Ueda (Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Japan) ran a randomised, double-blind, placebo-controlled, parallel-group trial registered as UMIN000028925, with the minimal erythema dose as primary outcome and skin moisture, transepidermal water loss and a visual analog scale as secondary outcomes.5 Eighty-one people were recruited, 23 were enrolled (astaxanthin n = 12, placebo n = 11), all finished, and one astaxanthin participant was excluded from analysis "because of an aberrant serum bilirubin level before and after supplementation", leaving 22 in a per protocol analysis.5 Each capsule held 4 mg astaxanthin from H. pluvialis processed by "dispersant technology".5 The authors report that the astaxanthin group "showed a significant increase in MED from baseline compared with the placebo group", a mean increase of "approximately 5 mJ/cm2".5 The raw MED after supplementation was 44.0 ± 6.2 mJ/cm2 with placebo and 48.4 ± 8.2 mJ/cm2 with astaxanthin (p = 0.162), so the between-group comparison of raw values was not significant.5 Skin moisture fell less at 1.15 MED seven days after irradiation with astaxanthin, but "the comparable decrease of moisture was observed" at 1.32 MED in both groups, and no difference in transepidermal water loss was seen at the irradiated area.5 Of seven subjective items, two ("improvement of rough skin" and "texture") were "significantly improved in the astaxanthin group compared with the placebo group", and the others showed no significant difference.5 The paper states that "the responsible physician reported no problems with the safety of astaxanthin".5 The authors list as limitations that they "did not estimate the exact dietary intake of astaxanthin by participants", that the mechanism "was not elucidated", and that the relationship between plasma or skin astaxanthin concentration and protection "was not analyzed".5 The sample size was set at 10 from the authors' own earlier trial, the group was 20 women and 2 men, and the funding line reads "This research received no external funding" while the conflict statement names FUJIFILM Corporation "a sponsor and funder of this study".5
Deeper analysis: Zhou and colleagues, meta-analysis of skin ageing, Nutrients 2021
Zhou and colleagues (Key Laboratory for Special Medical Food Process in Hunan Province, Central South University of Forestry and Technology, China) searched PubMed, Scopus and Web of Science for studies of astaxanthin and human skin ageing and pooled the randomised trials with Review Manager 5.4.6 Oral astaxanthin improved moisture (SMD 0.53; 95% CI 0.05 to 1.01; I2 52%; p = 0.03) and elasticity (SMD 0.77; 95% CI 0.19 to 1.35; I2 75%; p = 0.009) and did not significantly change wrinkle depth (SMD -0.26; 95% CI -0.58 to 0.06; I2 0%; p = 0.11) against placebo.6 The authors call their findings "preliminary" because few trials (fewer than 10) were pooled, each with fewer than 100 people, and write that "most of them had a relatively unclear RoB, resulting in relatively poor study quality".6 They add that commercial interests in several studies may have contributed to "the low reliability of current data".6 The review's funding line reads "Authors have received no funds for this study" while its acknowledgments name two Hunan provincial grants, and the authors declare no conflict of interest.6
Deeper analysis: Kumalic and colleagues, semen parameters, Radiology and Oncology 2020
Kumalic and colleagues (Division of Obstetrics and Gynecology, University Medical Centre Ljubljana, Slovenia) ran the trial from November 2014 to January 2019, registered as NCT02310087, in infertile men with oligospermia with or without asthenozoospermia or teratozoospermia defined by WHO 2010 criteria.7 Of 256 men assessed, 126 declined and 50 did not meet criteria; 80 were randomised to 16 mg astaxanthin daily or placebo, 8 dropped out "for personal reasons" (10%) and 72 were analysed.7 After three months, astaxanthin did not change total sperm number, concentration, motility, morphology, DNA fragmentation, mitochondrial membrane potential or serum FSH.7 The astaxanthin group went from 24.6 ± 28.6 to 31.7 ± 33.4 million per ejaculate (p = 0.186) and from 7.0 ± 5.6 to 9.2 ± 7.9 million/ml (p = 0.100), while the placebo group rose significantly, which the authors say "could reflect the beneficial psychological effect of placebo".7 The authors name as limitations that "one-third of patients had only a few mobile or immobile spermatozoa" in the semen analysis and that "a relatively high proportion of patients declined to participate".7 The manufacturer Sensilab donated the capsules, and the authors disclosed no potential conflicts of interest.7
Deeper analysis: Hecht and colleagues, digital eye strain in children, Advances in Therapy 2025
Hecht and colleagues reported an 84-day randomised, double-blind, placebo-controlled trial in 64 children aged 10 to 14 years with 4 or more hours of daily screen time and "mild to moderate" computer vision syndrome symptoms, registered as NCT05602402.8 The primary outcome was the CVS-Questionnaire, and 4 mg astaxanthin daily lowered it by 4.00 ± 4.05 units from baseline against 1.72 ± 3.61 on placebo, "a 20% between group difference".8 The visual fatigue Likert scale was lower with astaxanthin (11.55 ± 5.78) than placebo (15.78 ± 7.12; p = 0.01), and stereopsis after visual load and the pupillary light reflex also differed from placebo.8 There was "no significant intergroup difference" in the Schirmer I test (tear production rose from baseline in the astaxanthin group), visual acuity, spherical equivalence, near point of accommodation, near exophoria, immune markers or safety variables.8 The PubMed record carries no funding statement but lists the publication type "Research Support, Non-U.S. Gov't", and its conflict statement says first author Karen Hecht is employed by AstaReal Inc., other authors by AstaReal India and AstaReal Singapore and by Fuji Chemical Industries, and two authors by Vedic Lifesciences, "a contract research organization engaged by Fuji".8 The PubMed record carries a summary and a conflict statement but no limitations passage, so the authors' stated limitations and the numbers of children per arm are not reported here.8
Doses reported in studies and on labels
| Source | Dose and form | Route and duration | People and comparator |
|---|---|---|---|
| Odeberg and colleagues 20031 | 40 mg astaxanthin as three lipid-based formulations or a commercial food supplement | Oral, single dose | 32 healthy men in an open parallel design1 |
| Khayyal and colleagues 20242 | 400 mg preparation equivalent to 8 mg astaxanthin, micellar or native | Oral, single dose with 240 mL water | 12 healthy men, crossover with 1-week washout2 |
| Coral-Hinostroza and colleagues 20043 | 10 mg, then 100 mg astaxanthin equivalents as diesters, 4 weeks apart | Oral, single dose with a meal | 3 men, no comparator3 |
| EFSA opinion 20204 | Maximum authorised level of 8 mg astaxanthin per day in food supplements (oleoresin at 40–80 mg/day) | Oral, daily food supplement | EU authorisation level assessed for adults, adolescents and children4 |
| Ito and colleagues 20185 | 4 mg astaxanthin capsule | Oral, daily for 9 weeks | 23 healthy adults enrolled, placebo comparator5 |
| Zhou and colleagues 20216 | Usually at least 3 mg/day in the pooled trials | Oral, usually with or after a meal; the randomised trials lasted 4 weeks to 16 weeks6 | Healthy adults, placebo comparator; 9 randomised trials6 |
| Kumalic and colleagues 20207 | 16 mg astaxanthin | Oral, daily for 3 months | 80 men randomised, placebo comparator7 |
| Hecht and colleagues 20258 | 4 mg astaxanthin soft capsule | Oral, daily for 84 days | 64 children aged 10 to 14 years, placebo comparator8 |
| Xanthin study, cited in Khayyal and colleagues 20242 | 12 mg per day, as described by the citing authors | Oral, 1 year | Kidney transplant recipients per the citing authors (not read at source)2 |
Side effects reported
Four of the studies above report on safety, and none lists an adverse event attributed to astaxanthin. In the 12-man pharmacokinetic study the authors write that "no clinically significant abnormalities were observed".2 The skin trial reports "no adverse events", with the exclusion of one astaxanthin participant for an aberrant serum bilirubin level that was present before and after supplementation.5 The semen trial reports "No adverse effects during the treatment were reported", and 8 of 80 men (10%) dropped out for personal reasons.7 The eye-strain trial in children found no significant intergroup difference in its safety variables.8 Animal toxicology is summarised in the EFSA opinion: the feed-additive panel confirmed that astaxanthin "was neither mutagenic nor carcinogenic" and set an acceptable daily intake (ADI) of 0.2 mg per kg body weight per day by applying an uncertainty factor of 200 to a lowest observed adverse effect level in rats for "the increased incidence of multinucleated hepatocytes".4
Bloodwork and markers
Sources in this part
The app lists no markers to monitor. The skin trial measured serum liver enzymes, bilirubin, creatinine, uric acid, lipids, glucose, electrolytes and blood counts at baseline and after 9 weeks for safety, and reports no severe changes.5 The semen trial measured serum FSH, and it did not change with astaxanthin.7
Regulatory and anti-doping status
In 2020 the EFSA Panel on Nutrition, Novel Foods and Food Allergens concluded that "an intake of 8 mg ATX per day from food supplements is safe for adults even in combination with the high exposure estimate to ATX from the background diet".4 The same opinion states that, with high background intake from fish and crustaceans, adolescents aged 14 to under 18 years reach the ADI, and that the ADI is exceeded in children below 14 years of age, "up to 524% in infants aged 4–6 months".4 In 2025 the same panel concluded that an algal meal from H. pluvialis containing about 5% astaxanthin is "safe at the intended new uses (dairy analogues, including beverage whiteners and fruit juices), provided that FS containing ATX are not consumed on the same day by children and adolescents".9 A text search of the 2026 WADA Prohibited List found no mention of astaxanthin, xanthophyll or carotenoid, so the list names no astaxanthin entry; the sources read give no ruling on whether any class-level section could apply.10 A DailyMed search for "astaxanthin" returned one label, for a multi-ingredient capsule product, and no single-ingredient astaxanthin label was identified.
What is not known
Sources in this part
The app lists 16 h, 50% and 6 h, and the sources cited give half-lives from 15.9 h to 52 h, bioavailability statements of 6% to 34% and 10–50%, and peak times of 3.67 h to 11.5 h, across different doses, formulations and participant numbers. Whether astaxanthin concentration in skin or plasma relates to the skin outcomes was not analysed in the skin trial, and the meta-analysis states that none of its included trials measured skin concentrations.5,6 None of the records read from the PubMed and ClinicalTrials.gov searches run for this compound reported astaxanthin's passage across the retinal barrier in people, one of two statements in the app's own notes; the other, mitochondrial membrane stabilisation, was not searched for. Among the trials described here, Hecht and colleagues enrolled children, and their limitations are not available in the PubMed record read.8
Frequently asked questions
What is the half-life of astaxanthin?
How long does astaxanthin take to reach its peak level?
What is the bioavailability of astaxanthin?
Is astaxanthin banned by WADA?
A text search of the 2026 WADA Prohibited List found no mention of astaxanthin.10 The sources read give no ruling on class-level sections of the list.
Has EFSA assessed astaxanthin supplements?
Did astaxanthin change semen parameters in a randomised trial?
What did a meta-analysis find for astaxanthin and skin?
Were side effects reported in astaxanthin trials?
The skin, semen and pharmacokinetic studies each report no adverse events or no clinically significant abnormalities, and the eye-strain trial found no significant intergroup difference in safety variables.5,7,2,8 The skin trial excluded one astaxanthin participant from analysis for an aberrant serum bilirubin level before and after supplementation, and 8 of 80 men (10%) in the semen trial dropped out for personal reasons.5,7
Guides, tools and comparisons
References
- Mercke Odeberg J, et al. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 2003. PMID 12885395
- Khayyal MT, et al. Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers. Eur J Drug Metab Pharmacokinet 2024. PMC11199261
- Coral-Hinostroza GN, et al. Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters. Comp Biochem Physiol C Toxicol Pharmacol 2004. PMID 15556071
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of astaxanthin for its use as a novel food in food supplements. EFSA J 2020. EFSA opinion 2020
- Ito N, et al. The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2018. PMC6073124
- Zhou X, et al. Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing. Nutrients 2021. PMC8472736
- Kumalic SI, et al. Effect of the Oral Intake of Astaxanthin on Semen Parameters in Patients with Oligo-astheno-teratozoospermia: A Randomized Double-blind Placebo-controlled Trial. Radiol Oncol 2020. PMC7877271
- Hecht KA, et al. Astaxanthin (AstaReal) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial. Adv Ther 2025. PMID 40014233
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of algal meal from Haematococcus pluvialis containing astaxanthin as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2025. EFSA opinion 2025
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list